Observational, genetic, and experimental data indicate that triglyceride rich lipoproteins
(TRLs) likely participate causally in atherothrombosis. Yet, robust clinical trial evidence that …

Background Experimental and clinical data suggest that reducing inflammation without
affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory …

Background High triglyceride levels are associated with increased cardiovascular risk, but
whether reductions in these levels would lower the incidence of cardiovascular events is …

Background Inflammation in the tumour microenvironment mediated by interleukin 1β is
hypothesised to have a major role in cancer invasiveness, progression, and metastases. We …

Many measures can control lipid risk factors for atherosclerosis. Yet, even with excellent
control of dyslipidemia, other sources of risk remain. Hence, we must look beyond lipids to …

Background Inflammation is causally related to atherothrombosis. Treatment with
canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin …

Background Canakinumab, a monoclonal antibody targeting interleukin-1β, reduces
inflammation and cardiovascular event rates with no effect on lipid concentrations. However …

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …

Background—Lipoprotein (a)[Lp (a)] is a low-density lipoprotein–like particle largely
independent of known risk factors and predictive of cardiovascular disease. Statins may …

Background Inflammation plays a fundamental role in atherothrombosis. Yet, whether direct
inhibition of inflammation will reduce the occurrence of adverse cardiovascular outcomes is …